Dr. Richard Scranton headshot

Dr. Richard Scranton

President of Global Product Development and Chief Medical Officer

Richard Scranton, M.D., M.P.H., is the President of Global Product Development and the Chief Medical Officer of Lyndra Therapeutics, responsible for advancing the LYNX™ drug delivery platform and evolving and overseeing portfolio strategy, current and future product development from preclinical through commercialization, and external partnerships and alliances. Dr. Scranton is a visionary leader with forward-thinking problem-solving skills and a flexible and can-do spirit. He has 20+ years of expertise in pharmaco-epidemiologic research, clinical epidemiology, health services research and clinical trials research.

Prior to joining Lyndra, Dr. Scranton held roles with increasing responsibility at Pacira Pharmaceuticals – including Chief Medical Officer from 2018-2020 – where he led the global development and advancement of EXPAREL, a non-opioid long-lasting injectable local anesthetic. Dr. Scranton also served as Chief Medical Officer at VeroScience, where his responsibilities included all aspects of clinical development, regulatory and pharmacovigilance of their investigational drugs. Dr. Scranton was appointed instructor in medicine at Harvard Medical School and associate physician in the division of aging at Brigham and Women’s Hospital, advancing to assistant professor in 2006. Dr. Scranton also served as associate medical director and research consultant for Phase V Technologies. Dr. Scranton was an assistant clinical professor of medicine at the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences and a senior research fellow at the Massachusetts Veterans Administration Epidemiology, Research and Information Center (MAVERIC).

Dr. Scranton has 15 years of combined federal service as a clinician, mentor, educator, administrator and researcher, and 20 years of clinical and drug development research experience. His efforts as Chief Medical Officer of VeroScience included overseeing the approval of a first-in-class centrally acting drug indicated for the treatment of type 2 diabetes. At Pacira his leadership of clinical trial and regulatory efforts resulting in expanded indications and successful studies in a pediatric patient population.

Dr. Scranton earned a Bachelor of Arts from the University of Tennessee and a Doctor of Medicine from the Quillen College of Medicine at Eastern Tennessee State University. He completed his internship and residency in internal medicine at the Naval Medical Center in Portsmouth, Va, and served as chief resident. He completed his Harvard General Medicine Fellowship and received a Master of Public Health from the Harvard School of Public Health. Dr. Scranton and his wife, Carol, have two sons. Dr. Scranton enjoys outdoor activities such as hiking, snow skiing and water skiing, and he is also an avid gardener and landscaper.

Member Highlight